Objectives:Accumulating evidence suggests that people living in cold regions have a higher risk of developing coronary atherosclerotic heart disease(CHD).Long non-coding RNAs(lncRNAs)have been implicated in the pathog...Objectives:Accumulating evidence suggests that people living in cold regions have a higher risk of developing coronary atherosclerotic heart disease(CHD).Long non-coding RNAs(lncRNAs)have been implicated in the pathogenesis and treatment of a variety of diseases.The present study aimed to investigate the serum level of lncRNA-taurine upregulated gene 1(TUG1)in patients with CHD and assess its potential as a diagnostic biomarker.This study aimes to investigate the serum level of lncRNA-TUG1 in patients with CHD and assess its potential as a diagnostic biomarker.Methods:The Gene Expression Omnibus(GEO)database was employed to identify the potential lncRNAs serving as biomarkers for CHD.To validate lncRNA-TUG1,232 subjects were enrolled in both test and diagnostic cohorts.Serum lncRNA-TUG1 levels were measured by RT-qPCR.The association between lncRNA-TUG1 levels and CHD severity was analyzed using Pearson's correlation test.Diagnostic value was assessed by receiver operating characteristic(ROC)curve analysis and compared with established cardiac biomarkers.Results:LncRNA-TUG1 was identified in the GEO database as a potential biomarker for CHD.Serum lncRNA-TUG1 levels were significantly higher in CHD patients compared with healthy controls and non-CHD patients.CRP levels also differed between CHD and non-CHD groups,while other biomarkers showed no significant differences.ROC curve analysis demonstrated that lncRNA-TUG1 could distinguish CHD from non-CHD patients,with an area under the curve(AUC)of 0.8916,which was higher than that of conventional biomarkers such as cTnI.At a cut-off value of 2.311,the sensitivity and specificity of lncRNA-TUG1 were 61.63%and 97.67%,respectively,surpassing the diagnostic performance of cTnI.Furthermore,lncRNA-TUG1 levels in CHD patients were positively correlated with SYNTAX scores from coronary angiography and increased with the severity of vascular stenosis.Conclusion:Elevated serum lncRNA-TUG1 levels in CHD patients suggest that lncRNA-TUG1 may serve as a novel and valuable diagnostic biomarker for CHD,with potential utility in differentiating CHD from other cardiac diseases.展开更多
目的探究食管鳞状细胞癌(ESCC)组织中长链非编码RNA-牛磺酸上调基因1(lncRNA-TUG1)的表达水平及临床意义。方法收集2013年10月至2015年10月在渭南市中心医院行外科手术治疗的103例ESCC患者的肿瘤组织及癌旁组织标本。采用实时定量PCR(re...目的探究食管鳞状细胞癌(ESCC)组织中长链非编码RNA-牛磺酸上调基因1(lncRNA-TUG1)的表达水平及临床意义。方法收集2013年10月至2015年10月在渭南市中心医院行外科手术治疗的103例ESCC患者的肿瘤组织及癌旁组织标本。采用实时定量PCR(real time qRT-PCR)法测定lncRNA-TUG1的表达水平。采用Cox比例风险回归模型分析ESCC患者预后的影响因素。结果lncRNA-TUG1在ESCC组织中的表达水平显著高于癌旁组织,差异有统计学意义(P<0.01)。lncRNA-TUG1的表达水平与患者的肿瘤分期、分化程度及淋巴结转移情况有关(P<0.05)。生存分析结果显示,lncRNA-TUG1高表达患者的5年生存率显著低于lncRNA-TUG1低表达患者(P<0.05)。淋巴结转移和lncRNA-TUG1高表达是ESCC患者预后生存的独立危险因素(P<0.05)。结论lncRNA-TUG1在ESCC组织中的表达水平较高,且与患者的预后显著相关。展开更多
[目的]检测长链非编码RNA-牛磺酸上调基因1(lncRNA-TUG1)在胃癌组织中的表达情况,分析lncRNA-TUG1表达与胃癌患者临床病理参数及预后的关系。[方法]收集入住的85例胃癌患者的癌组织及其癌旁正常胃组织,采用实时定量PCR(real-time PCR)...[目的]检测长链非编码RNA-牛磺酸上调基因1(lncRNA-TUG1)在胃癌组织中的表达情况,分析lncRNA-TUG1表达与胃癌患者临床病理参数及预后的关系。[方法]收集入住的85例胃癌患者的癌组织及其癌旁正常胃组织,采用实时定量PCR(real-time PCR)法检测组织样本中lncRNA-TUG1的表达水平。分析胃癌组织中lncRNA-TUG1表达与患者临床病理参数的关系,采用Kaplan-Meier生存模型分析lncRNA-TUG1表达对胃癌患者预后的影响。[结果]胃癌组织中lncRNA-TUG1表达水平显著高于癌旁正常胃组织(5.32±1.39 vs 1.24±0.31,t=-26.413,P<0.001),且lncRNA-TUG1表达与患者的肿瘤分化程度、浸润深度、淋巴结转移和TNM分期有关(P均<0.05)。Log-Rank检验结果显示,高表达lncRNATUG1胃癌患者的术后5年生存率和中位生存时间均显著低于低表达lncRNA-TUG1胃癌患者(P均<0.05)。[结论]胃癌组织中lncRNA-TUG1表达增加,且与患者较差的临床病理参数和不良预后相关。展开更多
目的探究纤维蛋白原样蛋白1(fibrinogen-like protein 1,FGL1)和膜联蛋白A11(annexin A11,ANXA11)对肺癌手术患者效用评估价值及与预后的相关性。方法将本院2020年1月至2023年12月接诊的98例肺癌患者纳入肺癌组,另选取98例健康人作为对...目的探究纤维蛋白原样蛋白1(fibrinogen-like protein 1,FGL1)和膜联蛋白A11(annexin A11,ANXA11)对肺癌手术患者效用评估价值及与预后的相关性。方法将本院2020年1月至2023年12月接诊的98例肺癌患者纳入肺癌组,另选取98例健康人作为对照组。受试者入院后分别于空腹状态下采取6 mL肘静脉血,采用ELISA法检测血清ANXA11水平,采用实时荧光定量PCR技术检测ANXA11表达水平。根据术后1个月肿瘤标志物变化、影像学表现和免疫功能指标变化情况分为治疗有效组(n=68)和无效组(n=30)。患者出院后均行12~36个月的随访,根据患者预后情况分为预后良好组(n=63)和预后不良组(n=35)。对比对照组和肺癌组/有效组和无效组/预后FGL1、ANXA11表达差异;ROC分析FGL1、ANXA11单一及联合检测对肺癌手术患者临床效用评估价值;Spearman分析FGL1、ANXA11表达与预后的关系。结果肺癌组FGL1和ANXA11表达水平明显高于对照组(均P<0.05);无效组FGL1和ANXA11表达水平明显高于有效组(均P<0.05);ROC结果显示FGL1、ANXA11单独及联合检测对肺癌手术患者效用评估的曲线线下面积分别为0.928,并且联合检测具有较高的特异性(95.59%)以及敏感度(90.00%),诊断价值显著高于单独检测ROC曲线线下面积(均P<0.05);预后不良组FGL1和ANXA11表达水平明显高于预后良好组(均P<0.05);Spearman相关性结果显示FGL1、ANXA11与肺癌手术患者预后呈显著正相关(r=0.771、0.793,均P<0.05)。结论肺癌患者的FGL1与ANXA11表达水平高于健康人,治疗无效者高于有效者,预后不良者高于良好者,二者单独及联合检测对患者手术治疗效用评估均有价值,且其与预后相关性显著。展开更多
基金supported by the China Postdoctoral Science Foundation(Special Support,Grant No.2018T110318)the Innovation and Entrepreneurship Training Program for College Students(Grant No.S202110226047).
文摘Objectives:Accumulating evidence suggests that people living in cold regions have a higher risk of developing coronary atherosclerotic heart disease(CHD).Long non-coding RNAs(lncRNAs)have been implicated in the pathogenesis and treatment of a variety of diseases.The present study aimed to investigate the serum level of lncRNA-taurine upregulated gene 1(TUG1)in patients with CHD and assess its potential as a diagnostic biomarker.This study aimes to investigate the serum level of lncRNA-TUG1 in patients with CHD and assess its potential as a diagnostic biomarker.Methods:The Gene Expression Omnibus(GEO)database was employed to identify the potential lncRNAs serving as biomarkers for CHD.To validate lncRNA-TUG1,232 subjects were enrolled in both test and diagnostic cohorts.Serum lncRNA-TUG1 levels were measured by RT-qPCR.The association between lncRNA-TUG1 levels and CHD severity was analyzed using Pearson's correlation test.Diagnostic value was assessed by receiver operating characteristic(ROC)curve analysis and compared with established cardiac biomarkers.Results:LncRNA-TUG1 was identified in the GEO database as a potential biomarker for CHD.Serum lncRNA-TUG1 levels were significantly higher in CHD patients compared with healthy controls and non-CHD patients.CRP levels also differed between CHD and non-CHD groups,while other biomarkers showed no significant differences.ROC curve analysis demonstrated that lncRNA-TUG1 could distinguish CHD from non-CHD patients,with an area under the curve(AUC)of 0.8916,which was higher than that of conventional biomarkers such as cTnI.At a cut-off value of 2.311,the sensitivity and specificity of lncRNA-TUG1 were 61.63%and 97.67%,respectively,surpassing the diagnostic performance of cTnI.Furthermore,lncRNA-TUG1 levels in CHD patients were positively correlated with SYNTAX scores from coronary angiography and increased with the severity of vascular stenosis.Conclusion:Elevated serum lncRNA-TUG1 levels in CHD patients suggest that lncRNA-TUG1 may serve as a novel and valuable diagnostic biomarker for CHD,with potential utility in differentiating CHD from other cardiac diseases.
文摘目的探究食管鳞状细胞癌(ESCC)组织中长链非编码RNA-牛磺酸上调基因1(lncRNA-TUG1)的表达水平及临床意义。方法收集2013年10月至2015年10月在渭南市中心医院行外科手术治疗的103例ESCC患者的肿瘤组织及癌旁组织标本。采用实时定量PCR(real time qRT-PCR)法测定lncRNA-TUG1的表达水平。采用Cox比例风险回归模型分析ESCC患者预后的影响因素。结果lncRNA-TUG1在ESCC组织中的表达水平显著高于癌旁组织,差异有统计学意义(P<0.01)。lncRNA-TUG1的表达水平与患者的肿瘤分期、分化程度及淋巴结转移情况有关(P<0.05)。生存分析结果显示,lncRNA-TUG1高表达患者的5年生存率显著低于lncRNA-TUG1低表达患者(P<0.05)。淋巴结转移和lncRNA-TUG1高表达是ESCC患者预后生存的独立危险因素(P<0.05)。结论lncRNA-TUG1在ESCC组织中的表达水平较高,且与患者的预后显著相关。
文摘[目的]检测长链非编码RNA-牛磺酸上调基因1(lncRNA-TUG1)在胃癌组织中的表达情况,分析lncRNA-TUG1表达与胃癌患者临床病理参数及预后的关系。[方法]收集入住的85例胃癌患者的癌组织及其癌旁正常胃组织,采用实时定量PCR(real-time PCR)法检测组织样本中lncRNA-TUG1的表达水平。分析胃癌组织中lncRNA-TUG1表达与患者临床病理参数的关系,采用Kaplan-Meier生存模型分析lncRNA-TUG1表达对胃癌患者预后的影响。[结果]胃癌组织中lncRNA-TUG1表达水平显著高于癌旁正常胃组织(5.32±1.39 vs 1.24±0.31,t=-26.413,P<0.001),且lncRNA-TUG1表达与患者的肿瘤分化程度、浸润深度、淋巴结转移和TNM分期有关(P均<0.05)。Log-Rank检验结果显示,高表达lncRNATUG1胃癌患者的术后5年生存率和中位生存时间均显著低于低表达lncRNA-TUG1胃癌患者(P均<0.05)。[结论]胃癌组织中lncRNA-TUG1表达增加,且与患者较差的临床病理参数和不良预后相关。
文摘目的探究纤维蛋白原样蛋白1(fibrinogen-like protein 1,FGL1)和膜联蛋白A11(annexin A11,ANXA11)对肺癌手术患者效用评估价值及与预后的相关性。方法将本院2020年1月至2023年12月接诊的98例肺癌患者纳入肺癌组,另选取98例健康人作为对照组。受试者入院后分别于空腹状态下采取6 mL肘静脉血,采用ELISA法检测血清ANXA11水平,采用实时荧光定量PCR技术检测ANXA11表达水平。根据术后1个月肿瘤标志物变化、影像学表现和免疫功能指标变化情况分为治疗有效组(n=68)和无效组(n=30)。患者出院后均行12~36个月的随访,根据患者预后情况分为预后良好组(n=63)和预后不良组(n=35)。对比对照组和肺癌组/有效组和无效组/预后FGL1、ANXA11表达差异;ROC分析FGL1、ANXA11单一及联合检测对肺癌手术患者临床效用评估价值;Spearman分析FGL1、ANXA11表达与预后的关系。结果肺癌组FGL1和ANXA11表达水平明显高于对照组(均P<0.05);无效组FGL1和ANXA11表达水平明显高于有效组(均P<0.05);ROC结果显示FGL1、ANXA11单独及联合检测对肺癌手术患者效用评估的曲线线下面积分别为0.928,并且联合检测具有较高的特异性(95.59%)以及敏感度(90.00%),诊断价值显著高于单独检测ROC曲线线下面积(均P<0.05);预后不良组FGL1和ANXA11表达水平明显高于预后良好组(均P<0.05);Spearman相关性结果显示FGL1、ANXA11与肺癌手术患者预后呈显著正相关(r=0.771、0.793,均P<0.05)。结论肺癌患者的FGL1与ANXA11表达水平高于健康人,治疗无效者高于有效者,预后不良者高于良好者,二者单独及联合检测对患者手术治疗效用评估均有价值,且其与预后相关性显著。
